Clinical Trials · NCT00743769
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
- Phase
- Phase 1
- Recruitment status
- Withdrawn
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Enrollment
- 0
- Start date
- Apr 2008
- Locations
- 1 site, United States
- Primary endpoint
- Evaluate safety parameters in single-ascending doses of Tβ4(42 mg, 140 mg, 420 mg or 1,260 mg per dose) administered intravenously to healthy volunteers, such as ECG, vital signs,lab tests, etc.